Eindhoven based med-tech start-up company Plasmacure, developing a chronic wound healing device Plasoma, closed a series A round of funding. The funding was raised with private investors, NextGen Ventures and East Netherlands Development Agency – Oost NL. NextGen Ventures is a fund built primarily on investments by the healthcare insurers Menzis and Friesland Zorgverzekeraar. The amount of funding has not been disclosed.

Plasmacure will use the investment to get CE marking and introduce the product to the market. The first focus is on diabetic foot wounds. This funding will support Plasmacure in developing the device for home use, and for treating other types of wounds.

“This funding is very important for us because it will enable us to bring the device to the people who need it and for whom there is no real help at this moment. We realize that we can really start helping these people and this feels great” – said the CEO and founder of the company, Bas Zeper.

Subscribe to IO on Telegram!

Want to be inspired 365 days per year? Here’s the opportunity. We offer you one "origin of innovation" a day in a compact Telegram message. Seven days a week, delivered around 8 p.m. CET. Straight from our newsroom. Subscribe here, it's free!

Subscribe!

More on Plasmacure here (more after the video)

The primary reason for Oost NL to invest in Plasmacure is that it makes healthcare more affordable. Treating persistently open wounds costs the Dutch healthcare budget €2 billion. Pieter Rhemrev, manager of the business unit Capital at Oost NL, says, “Plasmacure is handy, takes very little time to apply and is painless. It clearly advances the quality of life for the patient. With this investment, we are promoting result-oriented healthcare”.

Plasmacure has already shown its potential – and results – after the first clinical trial at VU Medical Center Amsterdam. This study with the participation of 20 patients demonstrated that more than half of the wounds reduced in size and two wounds (10%) healed completely during the two weeks treatment period.

Plasoma plasmacure
Plasoma plasmacure

Support us!

Innovation Origins is an independent news platform that has an unconventional revenue model. We are sponsored by companies that support our mission: to spread the story of innovation. Read more.

At Innovation Origins, you can always read our articles for free. We want to keep it that way. Have you enjoyed our articles so much that you want support our mission? Then use the button below:

Doneer

Personal Info

About the author

Author profile picture Bart Brouwers is co-founder and co-owner of Media52 BV, the publisher of innovationorigins.com.